- Amryt Pharma booked a full-year loss after rising revenue was more than offset by R&D, marketing and administrative costs.

Pre-tax losses for the year through December amounted to €25.7m, compared to losses of €26.1m on-year.

Revenue rose 13% to €14.5m owing to sales of its high cholesterol treatment Lojuxta.

Amryt said its lead development asset, AP101, continued to progress, having recently successfully completed an independent efficacy analysis of a clinical trial involving sufferers of rare genetic condition epidermolysis bullosa.

The committee recommended that the trial continue with a modest increase in the number of patients in the study, to 230 evaluable patients, to maintain 80% statistical power.

At 2:08pm: [LON:AMYT] Amryt Pharma share price was +0.15p at 12.53p

Story provided by